Emmaus Life Sciences Issues Statement In Response to Announcement by AFH Holding & Advisory

News provided by

Oct 10, 2012, 11:00 ET

TORRANCE, Calif., Oct. 10, 2012 /PRNewswire/ -- Emmaus Life Sciences, Inc., a specialty pharmaceutical and regenerative medicine company, today issued the following statement in response to an announcement issued October 9, 2012, by AFH Holding & Advisory, LLC.

Emmaus Life Sciences has a pending lawsuit in California against AFH Holding & Advisory, which was filed in July 2012. The Company believes the claims filed by AFH Holding & Advisory in Delaware appear to be nothing more than a reaction to the California lawsuit. The company believes AFH's claims are completely without merit and it will defend them vigorously.

About Emmaus Life Sciences
Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.

For more information, please visit www.emmauslifesciences.com.

Contacts:

Media:
Lori Teranishi for Emmaus Life Sciences, Inc.
415-981-1964
[email protected]

Investors:
Matt Sheldon for Emmaus Life Sciences, Inc.
310-279-5975
[email protected]

SOURCE Emmaus Life Sciences, Inc.